HPV vaccination: the beginning of the end of cervical cancer? - A Review

Memorias do Instituto Oswaldo Cruz

Volumn 104, Issue 1, 2009, Pages 1-10

  Lepique, Ana Paula ^a   Rabachini, Tatiana ^a   Villa, Luisa Lina ^a  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Brazil)

Author keywords

Anogenital cancers; Clinical trial; Human papillomavirus; Prophylactic vaccine; Therapeutic vaccine

Indexed keywords

HUMAN PAPILLOMAVIRUS;

EID: 62549120308     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/S0074-02762009000100001     Document Type: Article

References (89)

1. Achtar MS, Ibrahim R, Herrin E, Gause B, Steinberg S, Grollman F, Rahma O, Berstein S, Maruffi C, Berzofsky JA, Khleif SN 2005. Pre-immature dendritic cells pulsed with human papillomavirus 16 E7 peptide vaccine in advanced cervical cancer. J Clin Oncol 23: 2522-2533.
2. Alvarez-Salas LM, DiPaolo JA 2007. Molecular approaches to cervical cancer therapy. Curr Drug Discov Technol 4: 208-219.
3. Ault KA 2007. Human papillomavirus vaccines and the potential for cross-protection between related HPV types. Gynecol Oncol 107 (2 Suppl. 1): S31-33.
4. Ault KA 2008. Human papillomavirus vaccines: an update for gynecologists. Clin Obstet Gynecol 51: 527-532.
5. Ault KA, Future II Study Group 2007. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369: 1861-1868.
6. Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, Castellsagué X, Rusche SA, Lukac S, Bryan JT, Cavanaugh PF Jr, Reisinger KS, Protocol 016 Study Group 2006. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 viruslike particle vaccine in male and female adolescents and young adult women. Pediatrics 118: 2135-2145.
7. Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, Tortolero-Luna G, Kjaer SK, Muñoz N 2008. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 26 (Suppl. 10): K1-16.
8. Brown DR, Schroeder JM, Bryan JT, Stoler MH, Fife KH 1999. Detection of multiple human papillomavirus types in Condylomata acuminata lesions from otherwise healthy and immunosuppressed patients. J Clin Microbiol 37: 3316-3322.
9. Chen C-H, Wang T-L, Hung C-F, Yang Y, Young RA, Pardoll DM, Wu T-C 2000. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 60: 1035-1042.
10. Chu NR, Wu HB, Wu TC, Boux LJ, Siegel MI, Mizzen LA 2000. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7. Clin Exp Immunol 121: 216-225.
11. Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S 2003. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 88: 63-73.
12. Daftarian P, Mansour M, Benoit AC, Pohajdak B, Hoskin DW, Brown RG, Kast WM 2006. Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a waterin-oil emulsion. Vaccine 24: 5235-5244.
13. de Jong A, van Poelgeest MI, van der Hulst JM, Drijfhout JW, Fleuren GJ, Melief CJ, Kenter G, Offringa R, van der Burg SH 2004. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res 64: 5449-5455.
14. De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S 2008. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 124: 1626-1636.
15. Diaz-Chavez J, Hernandez-Pando R, Lambert PF, Gariglio P 2008. Down-regulation of transforming growth factor-β type II receptor (TGF-βRII) protein and mRNA expression in cervical cancer. Mol Cancer 7: 3-14.
16. Dillner J, Arbyn M, Dillner L 2007. Translational mini-review series on vaccines: monitoring of human papillomavirus vaccination. Clin Exp Immunol 148: 199-207.
17. D'Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, Westra WH, Gillison ML 2007. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 356: 1944-1956.
18. Einstein MH, Kadish AS, Burk RD, Kim MY, Wadler S, Streicher H, Goldberg GL, Runowicz CD 2007. Heat shock fusion proteinbased immunotherapy for treatment of cervical intraepithelial neoplasia III. Gynecol Oncol 106: 453-460.
19. Ferguson M, Heath A, Johnes S, Pagliusi S, Dillner J 2006. Collaborative Study Participants. Results of the first WHO international collaborative study on the standardization of the detection of antibodies to human papillomaviruses. Int J Cancer 118: 1508-1514.
20. Fiander AN, Tristram AJ, Davidson EJ, Tomlinson AE, Man S, Baldwin PJ, Sterling JC, Kitchener HC 2006. Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial. Int J Gynecol Cancer 16: 1075-1081.
21. Franco EL, Cuzick J, Hildesheim A, Sanjose S 2006. Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 24 S3: 171-177.
22. Frattini MG, Lim HB, Doorbar J, Laimins LA 1997. Induction of human papillomavirus type 18 late gene expression and genomic amplification in organotypic cultures from transfected DNA templates. J Virol 71: 7068-7072.
23. Frazer IH, Quinn M, Nicklin JL, Tan J, Perrin LC, Ng P, O'Connor VM, White O, Wendt N, Martin J, Crowley JM, Edwards SJ, McKenzie AW, Mitchell SV, Maher DW, Pearse MJ, Basser RL 2004. Phase I study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. Vaccine 23: 172-181.
24. Future II Study Group 2007. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356: 1915-1927.
25. Garcia F, Petry KU, Muderspach L, Gold MA, Braly P, Crum CP, Magill M, Silverman M, Urban RG, Hedley ML, Beach KJ 2004. ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 103: 317-326.
26. Garland SM, Steben M, Hernandez-Avila M, Koutsky LA, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Esser MT, Vuocolo SC, Nelson M, Railkar R, Sattler C, Barr E, 012 Study Investigators 2007. Noninferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like particle vaccines. Clin Vaccine Immunol 14: 792-795.
27. Giuliano AR, Tortolero-Luna G, Ferrer E, Burchell AN, de Sanjose S, Kjaer SK, Muñoz N, Schiffman M, Bosch FX 2008. Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine 26 (Suppl. 10): K17-28.
28. Gunn GR, Zubair A, Peters C, Pan ZK, Wu TC, Paterson Y 2001. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol 167: 6471-6479.
29. Hammes LS, Tekmal RR, Naud P, Edelweiss MI, Kirma N, Valente PT, Syrjänen KJ, Cunha-Filho JS 2007. Macrophages, inflammation and risk of cervical intraepithelial neoplasia (CIN) progressionclinicopathological correlation. Gynecol Oncol 105: 157-165.
30. Harmala LAE, Ingulli EG, Curtsinger JM, Lucido MM, Schmidt CS, Weigel BJ, Blazar BR, Mescher MF, Pennell CA 2002. The adjuvant effects of Mycobacterium tuberculosis Heat Shock Protein 70 Result from the rapid and prolonged activation of antigen-specific CD8+ T Cells in vivo. J Immunol 169: 5622-5629.
31. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G, Glaxo-SmithKline HPV Vaccine Study Group 2004. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364: 1757-1765.
32. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G, HPV Vaccine Study group 2006. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367: 1247-1255.
33. Hasan UA, Bates E, Takeshita F, Biliato A, Accardi R, Bouvard V, Mansour M, Vincent I, Gissmann L, Iftner T, Sideri M, Stubenrauch F, Tommasino M 2007. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol 178: 3186-3197.
34. Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, Schiller JT, Gonzalez P, Dubin G, Porras C, Jimenez SE, Lowy DR, Costa Rican HPV Vaccine Trial Group 2007. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 298: 743-753.
35. Hirunpetcharat C, Wipasa J, Sakkhachornphop S, Nitkumhan T, Zheng YZ, Pichyangkul S, Krieg AM, Walsh DS, Heppner DG, Good MF 2003. CpG oligodeoxynucleotide enhances immunity against blood-stage malaria infection in mice parenterally immunized with a yeast-expressed 19 kDa carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (MSP1(19)) formulated in oil-based Montanides. Vaccine 20: 2923-2932.
36. Hsieh CJ, Kim TW, Hung CF, Juang J, Moniz M, Boyd DA, He L, Chen PJ, Chen CH, Wu TC 2004. Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin. Vaccine 28: 3993-4001.
37. Hussain SF, Paterson Y 2005. What is needed for effective antitumor immunotherapy? Lessons learned using Listeria monocytogenes as a live vector for HPV-associated tumors. Cancer Immunol Immunother 54: 577-586.
38. Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Garland SM, Harper DM, Tang GW, Ferris DG, Steben M, Jones RW, Bryan J, Taddeo FJ, Bautista OM, Esser MT, Sings HL, Nelson M, Boslego JW, Sattler C, Barr E, Paavonen J 2007. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16 and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369: 1693-702.
39. Kaufmann AM, Nieland JD, Jochmus I, Baur S, Friese K, Gabelsberger J, Gieseking F, Gissmann L, Glasschröder B, Grubert T, Hillemanns P, Höpfl R, Ikenberg H, Schwarz J, Karrasch M, Knoll A, Küppers V, Lechmann M, Lelle RJ, Meissner H, Müller RT, Pawlita M, Petry KU, Pilch H, Walek E, Schneider A 2007. Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3). Int J Cancer 121: 2794-2800.
40. Kaufmann AM, Nieland J, Schinz M, Nonn M, Gabelsberger J, Meissner H, Müller RT, Jochmus I, Gissmann L, Schneider A, Dürst M 2001. HPV16 L1E7 chimeric virus-like particles induce specific HLA-restricted T cells in humans after in vitro vaccination. Int J Cancer 92: 285-293.
41. Kenter GG, Welters MJP, Valentijn ARPM, Löwik MJG, Berendsvan-der Meer DMA, Vloon APG, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, van der Burg SH, Melief CJM 2008. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res 14: 169-177.
42. Kim D, Monie A, He L, Tsai YC, Hung CF, Wu TC 2008. Role of IL-2 secreted by PADRE-specific CD4+ T cells in enhancing E7-specific CD8+ T-cell immune responses. Gene Ther 15: 677-687.
43. Kirma N, Hammes LS, Liu Y, Nair HB, Valente PT, Kumar S, Flowers LC, Tekmal RR 2007. Elevated expression of the oncogene c-fms and its ligand, the macrophage colony-stimulating factor-1, in cervical cancer and the role of transforming growth factor-ß1 in inducing C-FMS expression. Cancer Res 67: 1918-1926.
44. Koutsky L 1997. Epidemiology of genital human papillomavirus infection. Am J Med 102: 3-8.
45. Kumar S, Jones TR, Oakley MS, Zheng H, Kuppusamy SP, Taye A, Krieg AM, Stowers AW, Kaslow DC, Hoffman SL 2004. CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine. Infect Immun 72: 949-957.
46. Lehtinen M, Herrero R, Mayaud P, Barnabas R, Dillner J, Paavonen J, Smith P 2006. Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries. Vaccine 24: 233-241.
47. Lin Y, Kwon T, Polo J, Zhu Y, Coates S, Crawford K, Dong C, Wininger M, Hall J, Selby M, Coit D, Medina-Selby A, McCoin C, Ng P, Drane D, Chien D, Han J, Vajdy M, Houghton M 2008. Induction of broad CD4+ and CD8+ T-cell responses and crossneutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2 and nonstructural proteins 3, 4, and 5. J Virol 82: 7492-7503.
48. Mazibrada J, Rittà M, Mondini M, De Andrea M, Azzimonti B, Borgogna C, Ciotti M, Orlando A, Surico N, Chiusa L, Landolfo S, Gariglio M 2008. Interaction between inflammation and angiogenesis during different stages of cervical carcinogenesis. Gynecol Oncol 108: 112-120.
49. Melief CJ 2008. Cancer immunotherapy by dendritic cells. Immunity 29: 372-383.
50. Müller M 2005. Codon optimization of papillomavirus genes. Methods Mol Med 119: 433-444.
51. Müller M, Zhou J, Reed TD, Rittmüller C, Burger A, Gabelsberger J, Braspenning J, Gissmann L 1997. Chimeric papillomavirus-like particles. Virology 234: 93-111.
52. Niederkorn JY 2008. Emerging concepts in CD8(+) T regulatory cells. Curr Opin Immunol 20: 327-331.
53. NIH 2009a. Clinicaltrial.org [homepage on the Internet]. Bethesda: A service of the U.S. National Institute of Health. A study of amolimogene (ZYC101a) in patients with high grade cervical intraepithelial lesions of the uterine cervix [updated 2009 Feb 04; cited 2009 Feb 04]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00264732?term=nct00264732&rank=1.
54. NIH 2009b. Clinicaltrial.org [homepage on the Internet]. Bethesda: A service of the U.S. National Institute of Health. Immunotherapy of recurrent cervical cancers using dendritic cells (DCs) [updated 2009 Feb 04; cited 2009 Feb 04]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00155766?term=nct00155766&rank=1.
55. NIH 2009c. Clinicaltrial.org [homepage on the Internet]. Bethesda: A service of the U.S. National Institute of Health. MAGE-A3/ HPV 16 vaccine for squamous cell carcinoma of the head and neck [updated 2009 Feb 04; cited 2009 Feb 04]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00257738?term=nct00257738&rank=1.
56. NIH 2009d. Clinicaltrial.org [homepage on the Internet]. Bethesda: A service of the U.S. National Institute of Health. Surgery and vaccine therapy in treating patients with early cervical cancer [updated 2009 Feb 04; cited 2009 Feb 04]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00002916?term=NCT00002916&rank=1.
57. Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, Iversen OE, Høye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, von Krogh G, Lehtinen M, Paavonen J, Tamms GM, Giacoletti K, Lupinacci L, Esser MT, Vuocolo SC, Saah AJ, Barr E 2007. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 25: 4931-4939.
58. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, de Carvalho NS, Skinner SR, Harper DM, Hedrick JA, Jaisamrarn U, Limson GA, Dionne M, Quint W, Spiessens B, Peeters P, Struyf F, Wieting SL, Lehtinen MO, Dubin G, the HPV PATRICIA Study Group 2007. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369: 2161-2170.
59. Pahler JC, Tazzyman S, Erez N, Chen YY, Murdoch C, NOzawa H, Lewis CE, Hanahan D 2008. Plasticity in tumor promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response. Neoplasia 10: 329-340.
60. Palefsky JM, Berry JM, Jay N, Krogstad M, Da Costa M, Darragh TM, Lee JY 2006. A trial of SGN-00101 (HspE7) to treat highgrade anal intraepithelial neoplasia in HIV-positive individuals. AIDS 20: 1151-1155.
61. Park JS, Kim EJ, Kwon HJ, Hwang ES, Namkoong SE, Um SJ 2000. Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. J Biol Chem 275: 6764-6769.
62. Pedersen C, Petaja T, Strauss G, Rumke HC, Poder A, Richardus JH, Spiessens B, Descamps D, Hardt K, Lehtinen M, Dubin G, HPV Vaccine Adolescent Study Investigators Network 2007. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 40: 564-571.
63. Phelps WC, Howley PM 1987. Transcriptional trans-activation by the human papillomavirus type 16 E2 gene product. J Virol 61: 1630-1638.
64. Poggi A, Zocchi MR 2008. Role of bone marrow stromal cells in the generation of human CD8+ regulatory T cells. Hum Immunol 69: 755-759.
65. Reisinger KS, Block SL, Lazcano-Ponce E, Samakoses R, Esser MT, Erick J, Puchalski D, Giacoletti KE, Sings HL, Lukac S, Alvarez FB, Barr E 2007. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 26: 201-209.
66. Ritz U, Momburg F, Pilch H, Huber C, Maeurer MJ, Seliger B 2001. Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma. Int J Oncol 19: 1211-1220.
67. Roman LD, Wilczynski S, Muderspach LI, Burnett AF, O'Meara A, Brinkman JA, Kast WM, Facio G, Felix JC, Aldana M, Weber JS 2007. A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia. Gynecol Oncol 106: 558-566.
68. Ronco LV, Karpova AY, Vidal M, Howley PM 1998. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev 12: 2061-2072.
69. Schiffman M, Kjaer SK 2003. Chapter 2: natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 31: 14-19.
70. Schiller JT, Roden RBS 1995. Papillomavirus-like particles. Papillomavirus Rep 6: 121-128.
71. Schlecht NF, Platt RW, Duarte-Franco E, Costa MC, Sobrinho JP, Prado JC, Ferenczy A, Rohan TE, Villa LL, Franco EL 2003. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst Monogr 95: 1336-1343.
72. Schwarz TF, Leo O 2008. Immune response to human papillomavirus after prophylactic vaccination withAS04-adjuvanted HPV-16/18 vaccine: improving upon nature. Gynecol Oncol 110 (Suppl. 1): S1-10.
73. Sewell DA, Shahabi V, Gunn GR 3rd, Pan ZK, Dominiecki ME, Paterson Y 2004. Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7. Cancer Res 64: 8821-8825.
74. Srivastava P 2002. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 20: 395-425.
75. Stanley M, Villa LL 2008. Monitoring HPV vaccination. Vaccine (Suppl. 1): A24-27.
76. Stanley MA, Pett MR, Coleman N 2007. HPV: from infection to cancer. Biochem Soc Trans 35: 1456-1460.
77. Sutter G, Moss B 1992. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci USA 89: 10847-10851.
78. Syrjanen S 2005. Human papillomavirus (HPV) in head and neck cancer. J Clin Virol 32 (Suppl. 1): S59-S66.
79. Vandepapeliere P, Barrasso R, Meijer CJ, Walboomers JM, Wettendorff M, Stanberry LR, Lacey CJ 2005. Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination. J Infect Dis 192: 2099-107.
80. Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP, Brown DR, Ferenczy A, Harper DM, Koutsky LA, Kurman RJ, Lehtinen M, Malm C, Olsson SE, Ronnett BM, Skjeldestad FE, Steinwall M, Stoler MH, Wheeler CM, Taddeo FJ, Yu J, Lupinacci L, Railkar R, Marchese R, Esser MT, Bryan J, Jansen KU, Sings HL, Tamms GM, Saah AJ, Barr E 2006a. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 24: 5571-5583.
81. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ, Barr E 2005. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6: 271-278.
82. Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, Olsson SE, Høye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, Krogh G, Lehtinen M, Malm C, Tamms GM, Giacoletti K, Lupinacci L, Railkar R, Taddeo FJ, Bryan J, Esser MT, Sings HL, Saah AJ, Barr E 2006b. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95: 1459-1466.
83. Wan YY, Flavell RA 2008. TGF-beta and regulatory T cell in immunity and autoimmunity. J Clin Immunol 28: 647-659.
84. Wang SS, Hildesheim A 2003. Chapter 5: Viral and host factors in human papillomavirus persistence and progression. J Natl Cancer Inst Monogr 31: 35-40.
85. Welters MJP, Kenter GG, Piersma SJ, Vloon APG, Löwik MJG, Berends-van-der Meer DMA, Drijfhout JW, Valentijn ARPM, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, Melief CJM, van der Burg SH 2008. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res 14: 178-187.
86. WHO - World Health Organization [homepage on the Internet], Geneva. WHO HPV LabNet 2008 [updated 18 December 2008; cited 04 February 2009]. Available from: http://www.who.int/biologicals/areas/vaccines/hpv_labnet/en/index.html.
87. Wu T-C, Guarnieri FG, Staveley-O'Carroll KF, Viscidi RP, Levitsky HI, Hedrick L, Cho KR, August T, Pardoll DM 1995. Engineering an intracellular pathway for MHC class II presentation of HPV-16 E7. Proc Natl Acad Sci USA 92: 11671-11675.
88. Zhou J, Gissmann L, Zentgraf H, Müller H, Picken M, Müller M 1995. Early phase in the infection of cultured cells with papillomavirus virion. Virology 214: 167-176.
89. Zwaveling S, Mota SCF, Nouta J, Johnson M, Lipford GB, Offringa R, van der Burg SH, Melief CJM 2002. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 169: 350-358.